Role of Adverse Events Supervision in Clinical Trials in Neoadjuvant Treatment of 
Operable Stage III NSCLC

Role of Adverse Events Supervision in Clinical Trials in Neoadjuvant Treatment of 
Operable Stage III NSCLC

Background and objective Programmed cell death protein 1 (PD-1) combined with platinum containing dual drug chemotherapy is a new adjuvant treatment option for operable stage III non-small cell lung cancer (NSCLC), and the quality assurance of clinical trials of related drugs plays a crucial role in...

Full description

Bibliographic Details
Main Authors: Yun ZHANG, Shuang ZHOU, Wentao TAO, Rong LI
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2023-06-01
Series:Chinese Journal of Lung Cancer
Subjects:
neoadjuvant therapy
lung neoplasms
adverse events
supervision
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.23

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.23

Similar Items